Sofinnova Investments’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$50.7M Buy
+43,777
New +$51.7M 2.2% 13
2026
Q1
– Sell
-61,652
Closed -$66.3M – 84
2025
Q4
$66.3M Buy
+61,652
New +$59M 2.86% 11
2025
Q3
– Sell
-97,018
Closed -$75.6M – 68
2025
Q2
$75.6M Buy
97,018
+44,218
+84% +$34.4M 4.63% 3
2025
Q1
$43.6M Buy
52,800
+38,436
+268% +$32M 2.85% 10
2024
Q4
$11.1M Buy
+14,364
New +$11.9M 0.81% 30
2024
Q1
– Sell
-64,525
Closed -$37.6M – 82
2023
Q4
$37.6M Buy
+64,525
New +$37.7M 2.1% 12
2023
Q2
– Sell
-137,100
Closed -$47.1M – 59
2023
Q1
$47.1M Buy
+137,100
New +$46.2M 3.01% 8
2022
Q4
– Sell
-45,500
Closed -$14.7M – 60
2022
Q3
$14.7M Buy
+45,500
New +$14.4M 0.86% 26
2021
Q2
– Sell
-180,501
Closed -$33.7M – 72
2021
Q1
$33.7M Buy
180,501
+143,592
+389% +$28.1M 2.03% 12
2020
Q4
$6.23M Sell
36,909
-105,523
-74% -$15.8M 0.37% 46
2020
Q3
$21.1M Sell
142,432
-6,468
-4% -$1M 1.56% 15
2020
Q2
$24.4M Buy
+148,900
New +$22.9M 1.54% 17

Other funds holding LLY

Sofinnova Investments's LLY Position: Q3 2026 in Review

Sofinnova Investments opened a new position in Eli Lilly (LLY) in Q3 2026: 43,777 shares worth $50.7M. The stake represents 2.2% of the portfolio and ranks #13 among its holdings. This is a return to the name: Sofinnova Investments previously reported a position in LLY as recently as Q4 2025.

Sofinnova Investments first reported a position in LLY in Q2 2020 and has held it in 12 quarters since. The position peaked at $75.6M in Q2 2025. 4,568 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Sofinnova Investments held 43,777 shares of Eli Lilly worth $50.7M as of Q3 2026.
  • Eli Lilly was a new Sofinnova Investments position in Q3 2026.
  • Eli Lilly made up 2.2% of Sofinnova Investments's portfolio in Q3 2026, its #13 holding.
  • Sofinnova Investments first reported a position in Eli Lilly in Q2 2020 and has held it in 12 quarters since.
  • Sofinnova Investments's Eli Lilly position peaked at $75.6M in Q2 2025.
  • 4,568 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Sofinnova Investments's 13F filing for Q3 2026, filed 16 Nov 2026.